Viibryd and Breastfeeding

Since no studies have been done on breastfeeding and Viibryd (vilazodone), it is not known if the medication passes through breast milk in humans or if it could cause problems in nursing infants. If you are breastfeeding, consult your healthcare provider before using this drug. Together, you can weigh the potential benefits and risks to make an informed decision.

Is Viibryd Safe While Breastfeeding?

At this time, it is unknown if Viibryd™ (vilazodone) passes through human breast milk. The manufacturer recommends that Viibryd only be used in breastfeeding women if the benefits of the medication outweigh the potential risks to the nursing infant. Therefore, if you are nursing a child, talk with your healthcare provider before taking this medication.

More Information on Breastfeeding and Viibryd

Viibryd was shown to pass through the breast milk of rats. However, no research has been done to see if Viibryd passes through human breast milk. Although this lack of information is certainly frustrating, it is important to understand that studies of medications are rarely done in breastfeeding women, as this would usually expose an infant (who will not directly benefit from the medication) to possible risks.

Talking With Your Healthcare Provider

You should discuss breastfeeding and Viibryd with your healthcare provider. Each woman's situation is different, and you and your healthcare provider understand your situation best. After considering what you want and expect, as well as your current health situation, the two of you can make a shared decision that is right for you.
Healthy Pet, Healthy You

Viibryd Medication Information

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2016 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.